Sight Sciences, Inc., (SGHT) News
Filter SGHT News Items
SGHT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SGHT News Highlights
- For SGHT, its 30 day story count is now at 3.
- Over the past 20 days, the trend for SGHT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about SGHT are DEC and BODY.
Latest SGHT News From Around the Web
Below are the latest news stories about SIGHT SCIENCES INC that investors may wish to consider to help them evaluate SGHT as an investment opportunity.
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative ContractorsDecision ensures continued access to comprehensive outflow procedure enabled by OMNI® Surgical System technology for glaucoma patientsMENLO PARK, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, supports the decision announced by five Medicare Administrative Contractors (“MACs”) to withdraw their fin |
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye DiseaseInterventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six monthsMENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today an |
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System TechnologyProspective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI Surgical System technology MENLO PARK, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced t |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start of the trading week with a look at the biggest pre-market stock movers worth watching on Monday morning! |
Independent Chairman of Sight Sciences Picks Up 14% More StockInvestors who take an interest in Sight Sciences, Inc. ( NASDAQ:SGHT ) should definitely note that the Independent... |
The Sight Sciences, Inc. (NASDAQ:SGHT) Analysts Have Been Trimming Their Sales ForecastsOne thing we could say about the analysts on Sight Sciences, Inc. ( NASDAQ:SGHT ) - they aren't optimistic, having just... |
5 Risky Stocks to Buy Immediately, According to AIMan and machine are combining to recommend these 5 risky stocks to buy. |
Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2023 Earnings Call TranscriptSight Sciences, Inc. (NASDAQ:SGHT) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Sight Sciences’ Third Quarter 2023 Earnings Results Call. At this time, all participants are in a listen-only mode. After the speakers presentation there will be a question-and-answer session. [Operator Instructions]. Please […] |
Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2023 and withdrew its guidance for full year 2023. Recent Business and Financial Highlights Generated third quarter 2023 total revenue of $20.0 mill |
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue EstimatesEkso Bionics (EKSO) delivered earnings and revenue surprises of 22.58% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |